Creative Planning’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $245K | Buy |
176,566
+29,846
| +20% | +$41K | ﹤0.01% | 3587 |
|
|
2025
Q4 | $236K | Sell |
146,720
-135,775
| -48% | -$284K | ﹤0.01% | 3420 |
|
|
2025
Q3 | $771K | Sell |
282,495
-835
| -0.3% | -$2.78K | ﹤0.01% | 2360 |
|
|
2025
Q2 | $1.03M | Buy |
283,330
+53,660
| +23% | +$147K | ﹤0.01% | 1823 |
|
|
2025
Q1 | $441K | Buy |
229,670
+63,367
| +38% | +$129K | ﹤0.01% | 2400 |
|
|
2024
Q4 | $316K | Buy |
166,303
+50,131
| +43% | +$87K | ﹤0.01% | 2618 |
|
|
2024
Q3 | $153K | Buy |
116,172
+5,482
| +5% | +$7.32K | ﹤0.01% | 2927 |
|
|
2024
Q2 | $113K | Hold |
110,690
| – | – | ﹤0.01% | 2818 |
|
|
2024
Q1 | $203K | Hold |
110,690
| – | – | ﹤0.01% | 2562 |
|
|
2023
Q4 | $137K | Buy |
110,690
+262
| +0.2% | +$267 | ﹤0.01% | 2523 |
|
|
2023
Q3 | $126K | Buy |
+110,428
| New | +$142K | ﹤0.01% | 2354 |
|
|
2021
Q2 | – | Sell |
-14,653
| Closed | -$50K | – | 2069 |
|
|
2021
Q1 | $50K | Sell |
14,653
-30,999
| -68% | -$112K | ﹤0.01% | 2352 |
|
|
2020
Q4 | $128K | Buy |
45,652
+32,000
| +234% | +$93.4K | ﹤0.01% | 1992 |
|
|
2020
Q3 | $34K | Buy |
13,652
+782
| +6% | +$6.86K | ﹤0.01% | 1939 |
|
|
2020
Q2 | $175K | Hold |
12,870
| – | – | ﹤0.01% | 1563 |
|
|
2020
Q1 | $98K | Hold |
12,870
| – | – | ﹤0.01% | 1534 |
|
|
2019
Q4 | $81K | Sell |
12,870
-3,692
| -22% | -$17.5K | ﹤0.01% | 1775 |
|
|
2019
Q3 | $65K | Sell |
16,562
-474
| -3% | -$2.03K | ﹤0.01% | 1766 |
|
|
2019
Q2 | $82K | Sell |
17,036
-307
| -2% | -$1.75K | ﹤0.01% | 1762 |
|
|
2019
Q1 | $142K | Sell |
17,343
-2,245
| -11% | -$15.4K | ﹤0.01% | 1645 |
|
|
2018
Q4 | $108K | Buy |
19,588
+8,938
| +84% | +$69.9K | ﹤0.01% | 1619 |
|
|
2018
Q3 | $94K | Hold |
10,650
| – | – | ﹤0.01% | 1803 |
|
|
2018
Q2 | $106K | Sell |
10,650
-15,720
| -60% | -$157K | ﹤0.01% | 1761 |
|
|
2018
Q1 | $251K | Buy |
26,370
+15,720
| +148% | +$220K | ﹤0.01% | 1460 |
|
|
2017
Q4 | $158K | Hold |
10,650
| – | – | ﹤0.01% | 1666 |
|
|
2017
Q3 | $209K | Hold |
10,650
| – | – | ﹤0.01% | 1579 |
|
|
2017
Q2 | $153K | Buy |
10,650
+300
| +3% | +$3.8K | ﹤0.01% | 1677 |
|
|
2017
Q1 | $95K | Sell |
10,350
-500
| -5% | -$4.88K | ﹤0.01% | 1995 |
|
|
2016
Q4 | $113K | Sell |
10,850
-26,500
| -71% | -$228K | ﹤0.01% | 1782 |
|
|
2016
Q3 | $338K | Hold |
37,350
| – | – | ﹤0.01% | 1117 |
|
|
2016
Q2 | $279K | Sell |
37,350
-12,650
| -25% | -$110K | ﹤0.01% | 1090 |
|
|
2016
Q1 | $451K | Buy |
50,000
+25,000
| +100% | +$203K | ﹤0.01% | 790 |
|
|
2015
Q4 | $323K | Buy |
25,000
+20,000
| +400% | +$204K | ﹤0.01% | 956 |
|
|
2015
Q3 | $48K | Buy |
+5,000
| New | +$45.9K | ﹤0.01% | 2063 |
|
Other funds holding AKBA
VCM
VPM
Creative Planning's AKBA Position: Q1 2026 in Review
Creative Planning increased its Akebia Therapeutics (AKBA) stake by 20% in Q1 2026, buying an estimated $41K and bringing the position to 176,566 shares worth $245K. The position accounts for ﹤0.01% of the portfolio, ranked #3587.
Creative Planning first reported a position in AKBA in Q3 2015 and has held it in 34 quarters since. The position peaked at $1.03M in Q2 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.
- Creative Planning held 176,566 shares of Akebia Therapeutics worth $245K as of Q1 2026.
- Creative Planning bought 29,846 Akebia Therapeutics shares in Q1 2026, an estimated $41K.
- Akebia Therapeutics made up ﹤0.01% of Creative Planning's portfolio in Q1 2026, its #3587 holding.
- Creative Planning first reported a position in Akebia Therapeutics in Q3 2015 and has held it in 34 quarters since.
- Creative Planning's Akebia Therapeutics position peaked at $1.03M in Q2 2025.
- 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.
Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.